Cellebrite DI Ltd. CLBT
Cellebrite DI Ltd. (CLBT) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 2.91% (safety: no dividend). FY2025 revenue was $475.7M at a 16.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.14 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-27 | DA Davidson | Buy (init) |
| 2026-05-15 | Needham | Buy (main) |
| 2026-02-12 | Needham | Buy (main) |
| 2025-11-13 | JP Morgan | Overweight (main) |
| 2025-11-13 | Lake Street | Buy (main) |
| 2025-11-13 | B of A Securities | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.22 |
| Retained earnings / assets | -0.092 |
| EBIT / assets | 0.071 |
| Equity / liabilities | 1.066 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CLBT | Cellebrite DI Ltd. | 4/9 | 2.73 | 43.8 | +18.6% |
| PRCH | Porch Group, Inc. | 7/9 | -2.21 | — | +10.2% |
| XNET | Xunlei Ltd | 5/9 | 8.16 | 0.3 | +42.5% |
| SPT | Sprout Social, Inc. | 4/9 | -2.61 | — | +12.7% |
| XPER | Xperi Inc. | 2/9 | -1.39 | — | -9.2% |
| INTA | Intapp, Inc. | 5/9 | 0.19 | — | +17.1% |
| ALKT | ALKAMI TECHNOLOGY, INC. | 3/9 | -0.9 | — | +32.9% |
About Cellebrite DI Ltd.
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency. It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities. Further, the company offers professional services, such as training and certification services, and advanced services. It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel.
FAQ
Is CLBT financially healthy?
Cellebrite DI Ltd.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CLBT pay a dividend, and is it safe?
Yes. Cellebrite DI Ltd. pays a dividend yielding about 2.91% with a None payout ratio, rated “no dividend” for safety.
How profitable is CLBT?
In FY2025, Cellebrite DI Ltd. had a net margin of 16.5% and a return on equity of 16.2%.
What is CLBT's P/E ratio?
Cellebrite DI Ltd.'s trailing price-to-earnings (P/E) ratio is about 43.8×, based on its latest annual earnings.
What is the analyst price target for CLBT?
The average Wall-Street price target for Cellebrite DI Ltd. is $21.00, about 37.7% above the recent price, from 7 analysts.
Is CLBT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Cellebrite DI Ltd.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a P/E of about 43.8×, a dividend yield of 2.91%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.